Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy Medical Dialogues Bureau22 March 2020 6:15 AM GMTZolgensma is a one-time gene therapy designed to address the genetic root cause of the disease by replacing the function of the missing or nonworking...